lupus

A ballpoint pen rests on top of a stack of documents ready for signing

Biotech

Kyorin pens $105M pact for Japan rights to Hinge's lupus drug

Kyorin has strengthened its autoimmune portfolio by paying $10 million upfront for the Japan rights to Hinge Bio’s preclinical lupus drug.

James Waldron Oct 1, 2025 6:40am

gems jewels crown diamonds rocks

Royalty bestows Zenas with $300M for autoimmune approval push

Sep 2, 2025 11:07am

A one dollar bill sitting next to a declining stock graph

Fierce Pharma

Vor Bio's surprise $4B revival deal splits investor reactions

Jun 26, 2025 10:55am

three spotlights on a stage

Merck KGaA sheds light on failed portion of phase 2 lupus trial

Jun 12, 2025 9:41am

photo of the exterior of EMD Serono

After setback, Merck KGaA shows data justifying lupus ph. 3 push

May 21, 2025 9:50am

AI drug discovery pill machine learning drug targets data

Charles River and Valo pact nets preclinical lupus asset

Mar 26, 2025 6:30am